SecBot SecBot
SECBOTREPLAY Home › Report › ABT

ABT · Abbott Laboratories has preliminarily agreed to settle a shareholder…

ABBOTT LABORATORIES · 8-K filed Apr 17, 2026 at 16:04 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 17, 2026 at 16:04 ET

Abbott Laboratories has preliminarily agreed to settle a shareholder derivative lawsuit related to its 2022 infant formula recall. The settlement includes corporate governance reforms and a potential payment of up to $15.85 million in legal fees, subject to court approval on June 4, 2026. The company denies wrongdoing but is settling to avoid further litigation costs.

  • Settlement resolves shareholder derivative litigation stemming from Abbott's 2022 infant formula recall
  • Settlement includes corporate governance reforms but no admission of wrongdoing by Abbott or its executives
  • Plaintiffs' counsel may request up to $15.85 million in attorney fees and expenses, subject to court approval
  • Final settlement hearing scheduled for June 4, 2026, before the U.S. District Court for the Northern District of Illinois

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access